Illuccix® Approved in Denmark
News,
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been approved by the Danish Medicines Agency…
Read moreNews & Views
Telix Full Year Results 2024 Investor Webcast Notification
News,
Telix today advises that it will release its full year results and Australian Annual Report for the period ended 31 December 2024 on Thursday 20 February…
Read more
Statement on impact of U.S. tariffs
News,
Telix currently generates most of its revenue from U.S. sales of Illuccix®. Because of the “just-in-time” nature of radiopharmaceutical products, such products are generally manufactured in close proximity to the…
Read more
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
Telix today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform,…
Read more
Telix Completes Acquisition of RLS (USA) Inc.
Telix today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic…
Read more
Illuccix® Receives European Approval
Telix today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68…
Read more
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
Telix today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco,…
Read more
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
Telix today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4…
Read more
Scintimun® Commercialization Partnership with Curium Pharma
Telix today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (99mTc-besilesomab, also known as TLX66-CDx), a diagnostic…
Read more
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
Telix today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology…
Read more